Last reviewed · How we verify
Grazax-R
Grazax-R is an oral immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure under the tongue.
Grazax-R is an oral immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure under the tongue. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.
At a glance
| Generic name | Grazax-R |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Sublingual immunotherapy (SLIT) |
| Target | Grass pollen allergen (timothy grass, Phleum pratense) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Grazax-R contains a standardized grass pollen allergen extract administered sublingually to induce immune tolerance. The drug works by shifting the immune response from allergic (Th2-mediated) to regulatory/tolerant (Treg-mediated), reducing allergic symptoms upon natural grass pollen exposure. This sublingual immunotherapy approach allows for at-home administration and aims to provide long-term symptom relief and reduced medication dependence.
Approved indications
- Grass pollen-induced allergic rhinitis and/or allergic asthma
Common side effects
- Oral pruritus
- Throat irritation
- Ear pruritus
- Mouth edema
- Local allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Grazax-R CI brief — competitive landscape report
- Grazax-R updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI